These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 27020587)

  • 21. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
    Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
    von Moos R; Koeberle D; Schacher S; Hayoz S; Winterhalder RC; Roth A; Bodoky G; Samaras P; Berger MD; Rauch D; Saletti P; Plasswilm L; Zwahlen D; Meier UR; Yan P; Izzo P; Klingbiel D; Bärtschi D; Zaugg K;
    Eur J Cancer; 2018 Jan; 89():82-89. PubMed ID: 29241084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy.
    Chang YK; Tseng HH; Leung CM; Lu KC; Tsai KW
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
    Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
    PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.
    Sclafani F; Gonzalez D; Cunningham D; Hulkki Wilson S; Peckitt C; Tabernero J; Glimelius B; Cervantes A; Dewdney A; Wotherspoon A; Brown G; Tait D; Oates J; Chau I
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
    Sclafani F; Chau I; Cunningham D; Hahne JC; Vlachogiannis G; Eltahir Z; Lampis A; Braconi C; Kalaitzaki E; De Castro DG; Wotherspoon A; Capdevila J; Glimelius B; Tarazona N; Begum R; Lote H; Hulkki Wilson S; Mentrasti G; Brown G; Tait D; Oates J; Valeri N
    Sci Rep; 2018 Jan; 8(1):1445. PubMed ID: 29362371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
    Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
    Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
    Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
    Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
    Derbel O; Wang Q; Desseigne F; Rivoire M; Meeus P; Peyrat P; Stella M; Martel-Lafay I; Lemaistre AI; de La Fouchardière C
    BMC Cancer; 2013 Apr; 13():200. PubMed ID: 23617638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Total Lymph Node Count on Staging and Survival After Neoadjuvant Chemoradiation Therapy for Rectal Cancer.
    Hall MD; Schultheiss TE; Smith DD; Fakih MG; Kim J; Wong JY; Chen YJ
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S580-7. PubMed ID: 25956577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
    Hu-Lieskovan S; Vallbohmer D; Zhang W; Yang D; Pohl A; Labonte MJ; Grimminger PP; Hölscher AH; Semrau R; Arnold D; Dellas K; Debucquoy A; Haustermans K; Machiels JP; Sempoux C; Rödel C; Bracko M; Velenik V; Lenz HJ
    Clin Cancer Res; 2011 Aug; 17(15):5161-9. PubMed ID: 21673069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.
    Peng J; Lv J; Peng J
    Int J Colorectal Dis; 2021 Aug; 36(8):1781-1790. PubMed ID: 33760952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
    Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
    PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
    Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
    Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indications for Lateral Pelvic Lymph Node Dissection Based on Magnetic Resonance Imaging Before and After Preoperative Chemoradiotherapy in Patients with Advanced Low-Rectal Cancer.
    Akiyoshi T; Matsueda K; Hiratsuka M; Unno T; Nagata J; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S614-20. PubMed ID: 25896145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.
    Sclafani F; Gonzalez D; Cunningham D; Hulkki Wilson S; Peckitt C; Giralt J; Glimelius B; Roselló Keränen S; Wotherspoon A; Brown G; Tait D; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1430-6. PubMed ID: 24582914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.